Patients diagnosed with MS according to the NCEP-ATPIII criteria who were receiving standard of care were assigned to either curcuminoids ( C3 complex ( ) ; 1000 mg/day ; n = 50 ) or placebo ( n = 50 ; matched with drug capsules in shape and color ) for 8 weeks .